Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKODYL vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4. Metabolized to 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to plasma albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3–0.7 L/kg; clinical meaning: distributes into total body water, with higher Vd in neonates and patients with hepatic cirrhosis.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral (immediate-release): 80–100%; oral (sustained-release): 80–100% (subject to first-pass metabolism); rectal: approximately 80%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
For GFR <30 m L/min: reduce dose by 50% and monitor serum levels; for GFR 30-60 m L/min: reduce dose by 25%.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or use alternative agent.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Loading dose: 5-7 mg/kg IV over 30 minutes; maintenance: 0.5-1 mg/kg/hour IV continuous infusion or 10-20 mg/kg/day orally divided every 8-12 hours; adjust to achieve serum levels 5-10 mcg/m L.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lower end of dosing range (300 mg/day) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Risk of toxicity due to narrow therapeutic index; monitor serum theophylline levels. Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias, or hepatic impairment. Smoking and certain drugs alter metabolism.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (unless on monitoring); uncontrolled seizure disorders; active peptic ulcer disease.
Hypersensitivity to theophylline or any component of the formulation.
High-fat meals may delay absorption; take consistently with food to avoid fluctuations. Charcoal-grilled foods and a high-protein, low-carbohydrate diet can increase metabolism of theophylline, reducing efficacy. Avoid concurrent use with caffeine-containing foods/beverages due to additive CNS stimulation.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Possible fetal tachycardia and jitteriness with maternal high doses; risk of neonatal withdrawal if used near term.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with milk-to-plasma ratio approximately 0.60-0.70. Concentrations in milk are about 2/3 of maternal serum levels. Irritability and sleep disturbance reported in nursing infants; monitor infant for signs of caffeine-like effects.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy may increase elimination of theophylline, especially in the third trimester, requiring dose adjustment. Monitor levels; may need 20-30% higher dose in third trimester. Postpartum, clearance decreases rapidly; reduce dose to prepregnancy levels.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
BRONKODYL (theophylline) has a narrow therapeutic index; serum levels should be monitored (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer, seizure disorders, or uncontrolled arrhythmias. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; smoking and rifampin decrease them. Use with caution in heart failure, hepatic impairment, and in elderly patients, as clearance is reduced.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take this medication exactly as prescribed; do not double doses if missed.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, tremors, palpitations, or seizures.,Do not change brands or formulations without consulting your doctor, as bioavailability may differ.,Regular blood tests are necessary to monitor theophylline levels.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKODYL vs AEROLATE JR, answered by our medical review team.
BRONKODYL is a Bronchodilator that works by Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKODYL and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKODYL is: Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKODYL and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKODYL is classified as Category C. BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Po. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.